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Background: FUSE binding protein1 (FBP1) is a transactivator of transcription of human c-myc proto-oncogene and
expressed mainly in undifferentiated cells. It is also present in differentiated normal cells albeit with very low
background. FBP1 is abundantly expressed in the majority of hepatocellular carcinoma tumors and has been
implicated in tumor development. Although it down-regulates the expression of proapoptotic p21 protein, it
is not known whether FBP1 also interacts and antagonizes the function of tumor suppressor protein p53.
Methods: Western blotting was carried out to detect the expression level of FBP1, p21 and p53, and also
p53 regulatory factors, BCCIP and TCTP; real-time quantitative PCR was done to determine the fold change in
mRNA levels of target proteins; immunoprecipitation was carried out to determine the interaction of FBP1 with p53,
BCCIP and TCTP. Cells stably knockdown for either FBP1; p53 or BCCIP were examined for p53 reporter activity under
normal and radiation-induced stress.
Results: FBP1 physically interacted with p53, impairing its transcription activity and reducing p53-mediated sensitivity
to cellular stress. Knockdown of FBP1 expression activated p53-mediated response to cellular stress while transient
expression of FBP1 in FBP-knockdown cells restored the inhibition of p53 activity. FBP1 not only interacted
with both BCCIP and TCTP, which, respectively, function as positive and negative regulators of p53, but also
regulated their expression under cellular stress. In FBP knockdown cells, TCTP expression was down-regulated
under radiation-induced stress whereas expression of BCCIP and p21 were significantly up-regulated suggesting
FBP1 as a potential regulator of these proteins. We hypothesize that the FBP1-mediated suppression of p53 activity
may occur via preventing the interaction of p53 with BCCIP as well as by FBP1-mediated regulation of p53 regulatory
proteins, TCTP and BCCIP. Since FBP1 suppresses p53 activity and is overexpressed in most HCC tumors, it may have a
possible role in tumorigenesis.
Conclusion: FBP1 physically interacts with p53, functions as a regulator of p53-regulatory proteins (TCTP and BCCIP),
and suppresses p53 transactivation activity under radiation-induced cellular stress. Since it is abundantly expressed in
most HCC tumors, it may have implication in tumorigenesis and thus may be a possible target for drug development.
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The tumor suppressor protein, p53, is a multifunctional
factor that plays key roles in cell growth and death [1].
When activated by various cellular stresses that disrupt
the fidelity of DNA replication and cell division, such as
radiation-induced DNA damage, p53 induces transcriptional* Correspondence: vnp22@njms.rutgers.edu
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regulatory and proapoptotic factors that regulate cell fate.
After DNA damage in a cell, the p53 pathway produces a
set of proteins that are directly involved in DNA repair
processes [2].
Loss of function of p53 as a consequence of mutation
has been shown in 50% of human cancers [3]. Animal
models lacking p53 have a higher predisposition to cancer
[4,5]. The ability of p53 to eliminate cells that poten-
tially may become cancerous relies on its ability to induce
programmed cell death, by regulating the expression ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of human cancers harbor transcriptionally active p53
in which the tumor suppression activity may have been
antagonized by other mechanisms. For example, overex-
pression of MDM2 promotes degradation of p53 [7] while
overexpression of TCTP (fortilin) blocks the binding of
p53 with Bax and inhibits p53-dependent apoptosis [8].
Some proteins can promote p53 transcription activity;
these include, BCCIP, a BRCA2 and CDKN1A (p21,
Cip1, and Waf1) that is important in DNA repair [9].
Abrogation of the interaction between p53 and TCTP-like
protein can retrieve p53 tumor-inhibiting activity. Small
molecules, such as nutlins [10,11] and RITA [12] can re-
trieve p53 tumor-suppressing activity by inhibiting the
interaction between MDM2 and p53 or binding with p53.
The mechanisms involved in impairing p53 transcription
activity are potentially important for drug development
for cancer treatment.
The p53 in Huh7 cells and cell lines derived from it
carries a mutation at codon 220 (Y220C) which has been
shown to be transcriptionally inactive [13-15]. In this re-
port, we demonstrated that mutant p53 in Huh7 cells is
transcriptionally active but remained suppressed due to
its interaction with fuse binding protein1 (FBP1). FBP1
regulates the transcription of the c-myc gene by binding
to an element called the far-upstream element (FUSE)
[16-18]. FBP1, which is over-expressed in 80% of HCC
[19], physically interact with p53 and suppresses its tran-
scription activity. While FBP-knockdown (FBP-kd) sig-
nificantly activated p53 transcription activity, transient
expression of FBP1 in FBP-kd Huh7 cells restored the
control phenotype inhibiting p53 functions suggesting a
novel mechanism by which p53 is impaired in this cell




Huh7 liver cancer cells were grown in Dulbecco’s modified
Eagle medium (DMEM) from Sigma (Saint Louis, MO)
supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT), 100 units/ml of nonessential amino acids
(Sigma), and 100 μg/ml of penicillin and streptomycin
sulfate (Sigma). Cells were grown at 37°C with 5% CO2.
Construction of stably transformed Huh7 cells knocked
down for FBP1, p53 or BCCIP
We generated stably transduced Huh7 cells with lenti-
virus vectors encoding shRNA targeting FBP1, p53, or
BCCIP (Santa Cruz, CA) or with empty vector alone
(SC-108080) following the manufacturer’s protocol. As a
control, Huh7 cells were infected with control lentiviral
particles with empty vector (Santa Cruz, SC-108080). Stable
clones were selected after several passages via puromycinselection in DMEM medium containing three μg/mL of
puromycin (Santa Cruz, CA).Stable knockdown of expres-
sion of targeted protein was confirmed by Western blot
analysis as compared to cells transformed with a vector
alone.Transient expression of FBP1 in FBP-kd cells
For transient expression of FBP in FBP-kd cells, we con-
structed shRNA resistant FBP expression clone (pCIA-
CMV-FBP) by mutating the siRNA target sequence
without changing the amino acid sequence. The lentivirus
based FBP1 shRNA targeting codons 248–254 in the cen-
tral domain and codon 560–566 in the C-terminal region
of FBP1. Point mutations were carried out at codons 251,
252, 562 and 563 without any change in the amino acid
sequence (Figure 1C). We confirmed the shRNA resist-
ance by transient expression of FBP1 in FBP-kd cells.Expression and purification of p53
E. coli BL21 cells transformed with pET11GTK-p53 plas-
mid were grown at 37°C in LB medium with 100 μg/ml
ampicillin until an OD595 of 0.5 was achieved; the cells
were then supplemented with 0.4 mM IPTG. Cells were
incubated at 25°C for 3 h with vigorous shaking, then
chilled and harvested by centrifugation. The cell pellets
were washed once with 50 mM Tris–HCl containing
0.15 M NaCl, then resuspended in lysis buffer containing
0.1 M KCl, 2 mM EDTA, 20% glycerol, 25 mM HEPES
buffer (pH7.6), 2 mM DTT, and 1× cocktail of protease in-
hibitors (R1321, Fermentas). We treated the cells with
lysozyme (100 μg/ml) containing 0.1% NP40. After 15 min
incubation at 4°C, cells were subjected to three cycles of
freezing at −80°C and thawing, then sonicated at ampli-
tude 40 with three 15-sec pulses. The lysed cells were cen-
trifuged at 14,000 g at 4°C. The supernatant was mixed
with glutathione-Sepharose beads (Pharmacia) at a ratio of
0.5 mg beads per ml of supernatant. The suspension was
incubated at 4°C for 1 h and centrifuged at 1,500 rpm for
1 min. Beads were placed in a small column and washed
extensively with wash buffer containing 50 mM Tris–HCl
(pH 8.0) and 5% glycerol. The washed beads, resuspended
in 0.5 ml of 10 mM reduced glutathione (Sigma-Aldrich),
were incubated for 15 min at room temperature, then
centrifuged. The supernatant fraction containing eluted
GST-tagged p53 were pooled and diluted to 15-fold with a
buffer containing 20 mM HEPES (pH7.5), 50 mM NaCl,
0.1 mM EDTA, 10 mM β-mercaptoethanol, 10% glycerol
and protease cocktail inhibitor (Roche, USA). The diluted
fraction was then applied onto the FPLC Hi-Trap heparin
column (Pharmacia) and washed extensively with the
same buffer. We eluted p53 protein with a linear gradient
(0% to 80%) of 1.5 M NaCl in the same buffer for 20 min
(1 ml/min). Eluted fractions showing greater than 95%
Figure 1 FBP negatively affects p21 and BCCIP expression in Huh7 cells. (A) Stably FBP-knockdown (FBP-kd) Huh7 cells by expressing FBP1
targeting shRNA: Huh7 cells were transfected with lentivirus vector encoding FBP1 targeting shRNAs or with empty vector alone. Stable clones
(NP-4, NP-5) were selected after several passages via puromycin selection and were confirmed for stable knockdown of FBP1 expression by Western
blot analysis as compared to cells transformed with the vector alone (NP-2, NP-3). (B). Expression of p53 and p21 in FBP-kd cells. Huh7 cells stably
transduced with FBP1 shRNA (NP-4) or empty vector alone (NP-2) were grown for 48 h. Cell lysates were normalized with respect to protein
and Western blotted for the expression of FBP1, p53, p21, and actin. Lane 1, control Huh7 cells; lane 2, FBP-kd Huh7 cells; lane 3, Huh7 cells transduced
with a lentivirus vector only. (C) Construction of FBP1 expression clone resistant to FBP1-shRNA. The FBP1-shRNA targeted sequences spanning codons
248 to 254 and from 560 to 567 were subjected to point mutation in FBP1 expression clone (pCIA-CMV-FBP) without changing the amino
acid sequence. (D) Transient expression of FBP1 in FBP-kd cells suppressed the expression of p21. FBP-kd cells were transfected with shRNA
resistant FBP1 expression clone ((pCIA-CMV-FBPSHR) or empty pCIA-CMV vector; 48-h later cells lysates were Western blotted for FBP1, p53 and p21 and
Actin. Lane 1, control Huh7 cells, lane 2, Huh7 cells transduced with lentiviral vector alone; lane 3, FBP-kd cells; lane 4, FBP-kd cells transfected with
empty vector; lane 5, FBP-kd cells transfected with shRNA resistant FBP1 expression clone. (E) Expression level of p21 in control and p53-kd, BCCIP-kd,
and FBP-kd Huh7 cells. Lane1, control Huh7 cells; lane 2, lentivirus vector control; lane 3, p53-kd; lane 4, BCCIP-kd and lane 5, FBP-kd Huh7 cells. A colon
cancer cell line, HCT116 without p53 (-/-) (lane 6) or with wild-type p53 (+/+) (lane 7) was used as controls.
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sodium phosphate (pH 7.8) containing 100 mM NaCl.
Expression and purification of FBP1
We transformed E. coli Rosetta (DE3) cells with pET28a-
FBP1 encoding His-tagged FBP1. Cells were grown at 37°C
in LB medium containing 30 μg/ml of kanamycin until an
OD595 0.4 was achieved. The culture medium was cooled
to 18°C and supplemented with 0.5 mM IPTG. After 16 h
of incubation with vigorous shaking at 18°C, cells were har-
vested and resuspended in a lysis buffer [20 mM Tris–HCl
pH 7.4, 200 mM NaCl, 1 mM β-mercaptoethanol, 10%glycerol, 1% triton-X 100, 5 mM imidazole]. The sus-
pension was supplemented with 2 mg/ml of ProteoBlock
protease inhibitor cocktail (Fermentas) and 2 mg/ml of
lysozyme. After 15 min incubation on ice, cells were soni-
cated and centrifuged at 14,000 g for 30 min. The clear
supernatant was applied onto the Ni-NTA column pree-
quilibrated with binding buffer [20 mM Tris–HCl pH 7.4,
200 mM NaCl, 10% glycerol, and 5 mM imidazole]. The
column was washed with the same buffer successively con-
taining 30 mM and 50 mM of imidazole. His tagged FBP1
was eluted from the column with 200 mM imidazole in the
same buffer. The eluted fractions were pooled, diluted
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5% glycerol, 0.5% NP-40, and 1 mM β-mercaptoethanol)
and applied onto the Hi-Trap Heparin column (Pharmacia).
After washing the column extensively with the same buf-
fer, FBP1 was eluted with a linear gradient (0% to 80%) of
1 M KCl in the same buffer for 20 min (1 ml/min). Eluted
fractions showing more than 95% purity on SDS-PAGE
(8%) were pooled and dialyzed against buffer containing
50 mM Tris–HCl (pH 7.5), 2 mM DTT, 100 mM NaCl,
and 50% glycerol.
Expression and purification of BCCIP
We transformed E. coli Rosetta (DE3) cells separately
with pET28a-BCCIPα and pET28a-BCCIP β encoding
His-tagged proteins. The transformed cells were grown
at 37°C in LB medium containing 30 μg/ml of kanamycin
until an OD595 0.4 was achieved. The medium was cooled
to 26°C and then supplemented with IPTG to a final
at 1.0 mM concentration. Cells were further incubated
at 26°C for 16 h with vigorous shaking, then chilled and
harvested by centrifugation. The cell pellets were resus-
pended in a lysis buffer supplemented with protease in-
hibitor cocktail and lysozyme as described. The cell lysates
were sonicated; centrifuged and clear supernatant was
applied onto Ni-NTA column and eluted as described
above for FBP1 purification. Fractions of 0.5 mL were col-
lected and analyzed by SDS-PAGE. The peak fraction with
greater than 95% purity was dialyzed and stored in −20°C.
Preparation of cell extract and western blotting
We washed the Huh7 cells with PBS three times, then
lysed them at room temperature in lysis buffer containing
1% SDS, 10% glycerol, 1 mM DTT and 10 mM Tris–HCl,
pH 6.8. We boiled the cell lysates for 5 min, cooled at
room temperature, then centrifuged at 13,000 rpm for
10 min at 4°C. We saved the supernatant and determined
the protein concentration (DC protein assay, Bio-Rad) in
each sample. An aliquot of the supernatant equivalent to
15 μg protein was resolved on 8% SDS-PAGE, and then
transferred to a nitrocellulose membrane (Schleicher and
Schuell Bioscience). The membrane was first blocked by
5% non-fat dry milk in PBS buffer containing 0.5% Tween
20 for 1 h at room temperature. The membrane was then
washed 4–5 times with the same buffer and treated over-
night at 4°C with 1:1000 diluted primary antibody of the
selected protein target (Santa Cruz Biotechnology). The
membrane was washed again with the same buffer four
times, then treated with 1:5,000 dilution of horseradish-
peroxidase-conjugated secondary antibody for 1 h at room
temperature and washed thoroughly. The membrane was
then incubated with HRP substrate (Western Lightning
Chemiluminescence Reagent, PerkinElmer Life Sciences)
for 10 sec to 1 min, exposed on FluorChem M or Kodak
X-Omat AR x-ray film (Eastman Kodak).Radiation survival assay
We determined the radiation sensitivity of Huh7 cells
(FBP1 normal and knockdown) by colony formation ex-
periments. We first did a pilot experiment with control
Huh7 cells to determine the number of cells to be plated
to obtain 50–150 surviving colonies per dish after a γ-
irradiation dose of 3Gy. Cells were plated on 100-mm
dishes 24 h before radiation treatment. We used a Cs-137
γ- irradiator to deliver 3-Gy to cells, and then incubated
the irradiated cells for 14 days. The colonies were fixed
with methanol and stained with 0.5% crystal violet. The
survival ratios were determined from the number of cells
plated. Cells in each dosage group were plated in tripli-
cate, and the experiments were repeated twice.
Isolation of total RNA and real-time RT-PCR
We isolated total RNA from cells using TRIzol® reagent
(Invitrogen) according to the manufacturer’s protocol.
One microgram of total RNA was used to synthesize
cDNA corresponding to the mRNA of FBP1, p21, BCCIP,
TCTP, p53, and GAPDH by reverse transcription as de-
scribed earlier. We used 50 ng of cDNA in Fast SYBR®
Green Master Mix (Applied Biosystems), with primers di-
rected to specific mRNA to do real-time quantitative PCR
using the Fast Real PCR System (Applied Biosystems) as
described [20,21]. Data were analyzed using 7500 software
(Applied Biosystems). The relative fold change in specific
mRNA copies was calculated by normalizing the amount
of GADPH mRNA in each sample. All experiments were
done in triplicate for each data point.
Luciferase reporter gene assay under radiation-induced
stress
The reporter plasmid, p53-Luc, and positive control plas-
mid pFC-p53 were purchased from Agilent Technologies
(Santa Clara, CA). MG-Luc plasmid (kindly provided by
Dr. Bert Vogelstein) carrying a mutation in the p53 bind-
ing sites was used as a negative control [22]. WWP-Luc
(also provided by Dr. Bert Vogelstein), is a reporter gene
with a 2.4-kb p21WAF1 promoter region [23]. Huh7 cells
were transfected with one μg of reporter vectors and 50 ng
of pRL-SV40 expressing Renilla luciferase as internal con-
trol with DMRIE-C reagent (Invitrogen) according to the
manufacturer’s instructions. After 48 h of transfection,
luciferase activity was measured according to the manu-
facturer’s protocol (Promega, Madison, WI). Assays were
done in four parallel sets.
Immunoprecipitation
Huh7 cells (5 × 106 cells per assay) were washed twice
with warmed 1 x PBS and then lysed in cold buffer con-
taining 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1%
Triton X-100, and 1x protease inhibitor cocktail (Roche
Applied Science). We also treated the lysates with 60 μg
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nonspecific RNA binding proteins that might be cap-
tured in FBP1 immunoprecipitation (FBP-IP) via RNA
bridging. We incubated the cell lysates with 2 μg of anti-
FBP1 antibody (FBP1 C-20; Santa Cruz Biotechnology)
for 1 h at 4°C, then added 20 μl of protein A/G Plus agar-
ose beads (Santa Cruz Biotechnology). The mixture was
then incubated overnight at 4°C. The immunoprecipitates
were collected by centrifugation at 2,500 rpm for 5 min at
4°C. After washing the pellets four times with lysis buffer,
we resuspended the immunoprecipitates in 1 × Laemmli
gel loading buffer. Samples were boiled and centrifuged to
pellet the agarose beads. The supernatant was subjected to
SDS-PAGE and Western blotted for the target proteins.
Results
Increased expression of p21 in FBP1 knockdown cells
We have previously shown that down-regulation of FBP1
by siRNA drastically reduced the replication of HCV sub-
genomic replicons in MH14 cells, whereas overexpression
of FBP1 significantly enhanced virus replication [24]. FBP1
has also been shown to suppress p21 [19] cell cycle regula-
tor. Since p21expression is also under the control of p53,
it was important to examine whether knockdown of FBP1
expression influences the expression of p21 and p53 in
Huh 7 cells. We, therefore, generated stable FBP-kd Huh7
cell lines NP-4 and NP-5 using FBP1 shRNA, and then
analyzed them for FBP1 expression (Figure 1A, lanes 4, 5).
We also used control lentivirus to generate stable cell lines
NP-2 and NP-3, as controls without affecting the ex-
pression of FBP1 (Figure 1A, lanes 2, 3). Although we ob-
served knock down of FBP1 expression by shRNA in
several colonies (Figure 1A), we used the NP-4 (lane 4)
colony as the stable FBP-kd cell line and the NP-2 (lane 2)
colony as the lentivirus control cell line. We then exam-
ined the level of expression of p21 and p53 in control
Huh7, lentivirus control (NP-2) and FBP-kd (NP-4) cells
(Figure 1B, lanes 1 through 3), noting that the p53 level
in both FBP-kd Huh 7 cells (NP-4) and control cells
remained unchanged. In contrast, p21 expression was en-
hanced in FBP1 knockdown cells (lane 2) but remained
suppressed in the control cells (lanes 1 and 3).
Transient expression of FBP1 in FBP1-knockdown cells
restored suppression of p21 expression
Since expression of p21 in FBP1-kd cells is significantly
enhanced while remained suppressed in the presence
of FBP1 in control Huh7 cells, we examined whether
transient expression of FBP1 in FBP-kd cells could re-
store the suppression of p21 expression. We, therefore,
constructed a shRNA resistant expression clone of FBP1
(pCIA-CMV-FBPSHR) by point mutations in the shRNA
targeted region in the central and C-terminal domains
of FBP1 without altering the amino acid sequence(Figure 1C). We transfected FBP1-shRNA resistant FBP1
clone (pCIA-CMV-FBPSHR) or empty pCIA-CMV vector
in FBP-kd Huh7 cells. After 48 h of transfection, cells were
γ-irradiated (3Gy) and 6 h later cells were lysed and Western
blotted for FBP1, p53, p21 and actin (Figure 1D). We
found that transient expression of FBP1 in FBP-kd Huh7
cells significantly suppressed p21 expression (lane 5) as
compared to control FBP-kd cells (lane 3) or FBP-kd cells
transfected with empty vector pCIA-CMV alone (lane 4).
This also indicated that irradiated FBP-kd cells expressing
transient FBP1 display p21-expression profile similar to
that seen in control Huh7 cells (lanes 1 and 2).
Knockdown of p53 or BCCIP abrogate p21 expression in
Huh7 cells
p21 is positively regulated by p53. A p53 regulatory pro-
tein, BCCIP, has also been shown to regulate p21 positively
via its interaction with p53. We, therefore, hypothesized
that enhanced expression of p21 in FBP-kd Huh7 cells
could be a result of its positive regulation by p53 and
BCCIP, which may be suppressed in the presence of FBP1
in control Huh7 cells. We tested this hypothesis using
Huh7 cells stably knockdown for p53 or BCCIP, and then
Western blotted their cell lysates for p21 expression. We
also used a colon cancer cell line HCT116 with p53 nega-
tive or positive phenotype. We found that as compared to
controls, down-regulation of p53 or BCCIP in Huh7 cells
drastically reduced the expression of p21 (Figure 1E, lanes
3, 4). Similar reduction in p21 expression was also ob-
served in p53−/− HCT116 cells as compared to p53+/+
control (Figure 1E, lanes 6, 7). We found that the basal level
of expression of p21 seen in control Huh7 cells (Figure 1E,
lanes 1, 2) was significantly enhanced in FBP-kd cells
(lane 5). These results indicate that increased expression
of p21 in FBP-kd cells may be the result of activation of
p53 and BCCIP, which may have remained suppressed in
the presence of FBP1 in control Huh7 cells. These results
further suggest that in Huh7 cells mutant p53 (Y220C) re-
ported to be transcriptionally inactive [25], may indeed be
active but its transcription activity may be strongly sup-
pressed by FBP1.
Expression of p53, p21, BCCIP and TCTP in control and
FBP-kd Huh 7 cells in response to cellular stress
Since p53 is involved in regulating and controlling the
induction of apoptotic and growth-arrest factors in
response to cellular stress, we examined whether FBP1
interferes in the function of p53 in Huh7 cells under
radiation-induced stress. We irradiated control Huh 7
cells and FBP-kd cells with 3-Gy of γ-irradiation. The ir-
radiated cells were further grown for 0, 3, 6 and 12 h, then
processed for preparation of cell lysates. An aliquot of cell
lysates of each set containing equivalent protein was sub-
jected to SDS-PAGE and Western blotting for FBP1, p53,
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were also determined by real-time RT-PCR.
We found that in control Huh7 cells, FBP1 expression
was significantly increased at 6 h post-irradiation, but
there was no change in the level of expression of p53
and p21 (Figure 2A, lane 3). In contrast, in FBP-kd cells,
expressions of both p53 and p21 were significantly enhanced
at 6–12 h post-irradiation (Figure 2A, lanes 7 and 8).
These results indicate that in the presence of FBP1 in con-
trol Huh7 cells, the expression of p53 and p21 remained
insensitive to irradiation treatment suggesting that the
p53-mediated response to cellular stress is inhibited by
FBP1. In contrast, increased expression of p21 in response
to irradiation in FBP-kd Huh7 cells suggests that the tran-
scription activity of p53 in control Huh7 cells may have
been inhibited in the presence of FBP1.
We further observed upregulation of translationally
controlled tumor protein (TCTP) in control Huh7 cells
at all-time points (Figure 2A, lanes 1–4) while its expres-
sion level in FBP-kd Huh7 cells was drastically reducedFigure 2 FBP interacts with p53 and its regulatory proteins, and regu
expression of p53, p21, BCCIP and TCTP in control and FBP-kd Huh 7 cells.
cells were grown for 0, 3, 6, and 12 h and examined for the expression of p
from cells grown for 0, 3, 6 and 12 h post-irradiation (B) Fold change in th
and FBP-kd Huh7 cells. Cells grown for 48 h were irradiated with 3-Gy of γ-
FBP1, p53, p21, BCCIP, and TCTP were determined by real-time quantitativ
irradiated control and FBP-kd cells, respectively. Lanes 1-4, show result
Co-immunoprecipitation of FBP1, p53 and BBCIP. IP was done with either (C)
were captured on protein A/G PLUS-agarose beads, resolved on 8% polyacryl
FBP1. (E) FBP, p53 and BCCIP form ternary complex in-vitro. We incubated 50
The complex was then subjected to FBP-IP, p53-IP or BCCIP-IP. The IP comple
Lanes 1-3, show ternary complex of FBP1-p53-BCCIP captured by immunopr
complexes between FBP1-p53, p53-BCCIP and FBP1-BCCIP, respectively.(Figure 2A, lanes 5–8), suggesting that FBP1 may be a
positive regulator of TCTP, which is also known as fortilin.
TCTP is a negative regulator of p53 transcription activ-
ity, functioning as an anti-apoptotic factor by interact-
ing with and destabilizing p53 [8,26]. The expression level
of BCCIP was marginally reduced in control Huh 7 cells
after 6–12 h post-irradiation (lanes 3 and 4), but was
significantly induced in FBP-kd cells within 6–12 h post-
irradiation (Figure 2A, lanes7, 8). BCCIP, also called TOK-1,
is an important cofactor for BRCA2 in tumor suppres-
sion, functioning as a positive regulator of p53 and a
modulator of CDK2 kinase activity by interacting with
p21 [9,27,28]. The specific induction of BCCIP in FBP-kd
cells suggests that BCCIP is negatively regulated by FBP1
in Huh 7 cells. These results were confirmed by deter-
mining fold change in the mRNA levels of p21, p53,
BCCIP and TCTP in irradiated control and FBP-kd
Huh7 cells (Figure 2B). The mRNA levels of p53, p21
and BCCIP were significantly enhanced in FBP-kd cells
within 6–12 h of post-irradiation (Figure 2B, bottomlates their expression. (A) Effect of radiation-induced stress on the
Cells grown for 48 h were irradiated with 3-Gy of γ-ray. The irradiated
53, p21, BCCIP and TCTP by Western blotting. Lanes 1-4, show results
e mRNA level of FBP1, p53, p21, BCCIP and TCTP in irradiated control
ray and grown for 0, 3, 6, and 12 h. Fold changes in mRNA level of
e PCR. Upper and lower panels show fold change in mRNA level in
s from cells grown for 0, 3, 6 and 12 h post irradiation. (C, D)
anti-FBP1 antibody or (D) anti-BCCIP antibody, and the IP complexes
amide SDS-PAGE gel and Western blotted for p53, BCCIP and TCTP and
0 ng of each of the recombinant FBP, p53 and BCCIP at 4oC for 30 min.
x was resolved by SDS-PAGE and Western blotted for FBP, p53 and BCCIP.
ecipitation of FBP, p53 and BCCIP. Lane 4-6 show the formation of binary
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cells (Figure 2B, top panel). In contrast, mRNA levels of
TCTP in irradiated FBP-kd cells were drastically reduced
as compared to the irradiated control Huh7 cells suggest-
ing a positive regulation of TCTP by FBP1.
Physical interaction of FBP1 with p53 and its regulatory
factors
We addressed the potential mechanisms by which FBP1
regulates p53 via interacting with p53 regulatory pro-
teins. To examine whether p53, BCCIP and TCTP, inter-
act with FBP1, we carried out immunoprecipitation from
the benzonase treated cell lysates of Huh 7 cells using
FBP1 antibody, and then Western blotted for p53, BCCIP,
and TCTP. We found that endogenous FBP1 interacts
with p53, as well as its two regulatory proteins, BCCIP and
TCTP (Figure 2C, and lane 3). We also did BCCIP-IP and
Western blotted for FBP1 and p53. As shown in Figure 2D,
BCCIP interacts with both p53 and FBP1 (lane 3). Based
on these results, it can be hypothesized that binding of
FBP1 with both p53 and its positive regulator BCCIP
may prevent their interaction, resulting in loss of BCCIP-
mediated activation of p53-transcription activity. In con-
trast, FBP1-mediated upregulation of TCTP expression, as
well as interaction of FBP1 -TCTP complex with p53, may
increase suppression of transcription activity of p53.
In order to further confirm physical interaction of FBP1
with p53 and BCCIP, we also carried out immunoprecipi-
tation on purified recombinant proteins of FBP1, p53 and
BCCIP. Five hundred nanograms of each of the purified
proteins were mixed together and subjected to immuno-
precipitation using antibody against FBP1, p53 or BCCIP
(Figure 2E). We found that FBP-IP, p53-IP or BCCIP-IP
captures all three proteins indicating the formation FBP1-
p53-BCCIP ternary complex (Figure 2E, lanes 1–3). We
also confirmed the formation of binary complexes of
FBP1 with p53 or BCCIP in addition to binary complex
formation between p53 and BCCIP (lanes 4–6). These re-
sults support our hypothesis that FBP1 directly interacts
with p53 and BCCIP which may be involved in suppress-
ing p21 expression.
Inhibition of p53 transcription activity is reversed in
FBP-kd Huh7 cells
We know that p21 is a direct target protein of p53 and
that its expression is regulated by p53. We hypothe-
sized that the transcription activity of p53 is impaired
in FBP1-expressing Huh7 cells. We first used p53-Luc
reporter plasmid to test this hypothesis. P53 reporter
activities were increased 2.5 fold by γ-irradiation at 4-Gy
dose in FBP-kd Huh7 cells while only a marginal increase
of approximately 0.2 fold occurred in irradiated control
cells that expressed FBP1 (Figure 3A, left panel). To con-
firm this, p21-Luc, which is regulated by the promoterDNA sequence of p21 gene, was transfected into con-
trol and FBP-kd Huh7 cells. As shown in Figure 3A
(right panel), p21 promoter activity was enhanced by
greater than 2.5 fold in FBP-kd Huh7 cells as compared to
0.25 fold increase in the control cells. These results dem-
onstrated that p53 transcription activity in Huh7 cells is
strongly inhibited by FBP1.
In order to confirm that observed activation of p53 in
FBP-kd cells is due to absence of FBP1, we transiently
expressed shRNA resistant FBP1 in FBP-kd cells. The
FBP-kd Huh7 cells were transfected with FBP1 express-
ing clone along with reporter plasmids. After 48 h post-
transfection cells were γ-irradiated and 6 h later analyzed
for expression of luciferase activity. We found that the
enhanced activation of p53 reporter activity in FBP-kd
cells was reversed and similar to control Huh7 when
FBP1 was transiently expressed in these cells (Figure 3B,
left panel). Similar results were obtained with p21 reporter
activity in the absence and presence of FBP1 in FBP-kd
cells (Figure 3B, right panel).
Knockdown of BCCIP and p53 abolishes radiation-induced
activation of p53 transcription activity in Huh7 cells
Since FBP1 also interacts with BCCIP, it is possible that
the effect of FBP1 in suppressing p53 activity could occur
through its interaction with BCCIP. Downregulation of
BCCIP has been reported in many cancers [29-31]. To
examine this possibility, we used stable BCCIP-knockdown
or p53-knockdown Huh7 cells and used them to examine
p53 transcription activity under radiation-induced stress
by means of p53-Luc and p21-Luc reporters system. We
found that both p53-Luc and p21-Luc reporter activities in
irradiated FBP-kd cells were 2.5-3 folds higher than in the
irradiated control cells while it was negligible in Huh 7
cells knockdown for either p53 or BCCIP (Figure 3C).
These results clearly indicate that the FBP1-mediated
inhibition of p53 transcription activity may occur as a
consequence of its ability to interact with both p53 and
BCCIP, and to prevent their interaction, which is essential
for activation of p53 activity.
Down-regulation of FBP1 in Huh7 cells confers radiation
sensitivity
p53 is a key protein in the cell cycle and programs cell
death by regulating the expression of several cellular fac-
tors. Lack of the transcription activity of p53 is always
associated with cell resistance to radiation. Using re-
porter vectors, we found that FBP1 down-regulation in
Huh7 cells activated p53 transcription activities. To con-
firm whether FBP1 is associated with radiation resistance
by inhibiting p53 transcription activity in Huh7 cells,
both control Huh7 and FBP-kd Huh7-cells were exposed to
irradiation, and colony formation was measured. As shown
in Figure 4A,B, FBP-kd cells showed higher sensitivity to
Figure 3 The transactivation activity of p53 is activated in FBP-kd Huh7 cells. (A) Activation of p53 transcription activity in FBP-kd Huh7
cells. Reporter vectors were transfected to control Huh 7 cells or FBP-kd cells as described in the Methods. Forty-eight hours later, cells
were irradiated with 4 Gy of γ-irradiation. Luciferase activities were measured 6-hour post-irradiation treatment. p53 reporter activity (left panel),
p21 reporter activity (right panel). (B) Transient expression of FBP1 in FBP-kd cells suppresses p53 transcription activities. FBP-kd cells were transfected
with shRNA resistant FBP1 expression clone (pCIA-CMV-FBPSHR) along with reporter vectors; 48-h later cells were irradiated with 3 Gy of γ-irradiation.
Luciferase activities were measured 6-hour post-irradiation treatment. p53 reporter activity (left panel), p21 reporter activity (right panel). (C) Relative
p53 transcription activity in BCCIP-kd, p53-kd and FBP-kd cells. Huh7 cells knockdown for BCCIP; p53 and FBP1 were transfected with reporter vectors;
48-h later cells were irradiated with 3 Gy of γ-irradiation. Luciferase activities were measured 6-hour post-irradiation treatment. p53 reporter activity (left
panel), p21 reporter activity (right panel).
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suggesting that FBP1 is important in impairing p53 tran-
scription activity in Huh7 cells.
Based on these results, we conclude that FBP1 physically
interacts with p53 and suppresses its transcription activity
by (i) directly inhibiting p53, (ii) by upregulating TCTP
and (iii) by down-regulating BCCIP. FBP1 not only inter-
acts with and down-regulates BCCIP, which is required
for activation of p53 activity, but also interacts with and
upregulates TCTP that negatively regulates the stability of
p53 and thus negatively affect p21 expression.
Discussion
FBP1 is a transactivator of the c-myc gene, which is
abundantly expressed in many cancers including HCCtumors [19,32,33]. Earlier we reported that FBP1 is
essential for HCV replication in MH14 cells derived from
Huh7 cells, an hepatocellular carcinoma cell line in which
FBP1 is abundantly expressed [24]. Knockdown of FBP1
in these cells drastically reduced HCV replication [24]. In
another study, Dharel et al. [34] have reported that in
Huh7 cells, p53 exerts an inhibitory effect on HCV repli-
cation while knockdown of p53 makes these cells more
permissive of viral replication. In Huh7 cells p53 contains
an Y220C mutation that is located outside of the con-
served p53-DNA binding domain and therefore not essen-
tial for the tertiary structure of the DNA binding surface
[25,35]. Kubicka et al. [25] have shown that in Huh7 cells,
the mutant p53 (Y220C) is not only dominant negative
but lacks p53-dependent target gene activation activity. It
Figure 4 FBP-kd increases the sensitivity of Huh7 cells to radiation
damage. A: Control and FBP –kd cells were exposed to γ-irradiation, and
planted on plates. Colonies formed after two weeks of post-irradiation.
B: The survival curves of control and FBP -kd cells exposed to
radiation treatment.
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DNA-binding core domain of p53 consisting of central
β-sandwich [36] that has been shown to be temperature
sensitive and had destabilizing effect on p53 at physiological
temperature [37]. Unexpectedly, Y220C mutation located
38 Å away from the DNA binding core on the periphery
of the β-sandwich, has also been shown to destabilize p53
and affect its function at physiological temperature [37].
Other studies have shown that transactivation activity of
Y220C mutant p53 in Huh7 cells is similar to that in
Chang liver cells and HepG2 cells containing wild-type
p53 [38-40]. Dharel et al. have also shown that mutant
p53 in Huh7 cells are transcriptionally active and exhibits
effective transactivation activity [34].
It is possible that in Huh7 cells, transactivation activity
of p53 is suppressed by some specific cellular factor such
as FBP1 and is not entirely inactivated due to Y220C
mutation. It is well known that binding of SV-40 large-
T-antigen to the wild-type p53 completely inactivates its
transcription activity [41]. In this context, we found
that FBP1 strongly and independently interacts with p53
as well as with the p53-regulatory proteins, BCCIP and
TCTP, and therefore may be responsible for the suppres-
sion of p53 activity in Huh7 cells. This possibility was sup-
ported by our finding that upon radiation-induced stress,
expression of both p53 and p21 was significantly en-
hanced in FBP-kd cells but remained nearly unchanged in
control Huh7 cells (Figure 2A,B). We further found thatFBP1 modulates the expression of TCTP and BCCIP,
which, respectively, function as negative and positive regu-
lators of p53. Under radiation-induced stress, the expres-
sion of TCTP is strongly decreased in FBP-kd cells while
BCCIP expression is significantly induced within 6–12 h
after irradiation (Figure 2A,B). Increased BCCIP ex-
pression under conditions of cellular stress may enhance
p53 transactivation activity. Similarly, down-regulation of
TCTP expression may relieve p53 from its inhibitory ef-
fect in FBP1 knockdown Huh7 cells. Using reporter assay,
we confirmed significant transactivation of p53 activity
in FBP-kd cells but nearly inactive in control Huh7 cells
(Figure 3A) and completely abolished in BCCIP-kd or
p53-kd cells (Figure 3C). In order to confirm that observed
activation of p53 activity in FBP-kd cells is due to positive
regulation of p53 in the absence of FBP1, we carried out
transient expression of shRNA resistant FBP1 in FBP-kd
cells. We found that the transient expression of FBP1
strongly inhibited activation of p53 activity similar to as
observed in the control Huh7 cells (Figure 3B).
The p53 has two major functions including negative
regulation of cell growth and the induction of apoptosis
[42]. Following exposure to ionizing radiation, cells with
functional p53 are arrested in G1 phase while cells with
non-functional p53 are not arrested at G1 checkpoint [42].
Huh7 cells are significantly resistant to radiation-induced
stress [43] that may largely be attributed to the presence
of inactive p53 [44]. We also found significantly high
resistance in Huh7 cells exposed to γ-irradiation. In con-
trast, FBP-kd Huh7 cell was highly sensitized to γ-irradiation
as compared to the control Huh7 cell. At the exposure of
as low as 2Gy, approximately 70 % of the loss of cell sur-
vival in FBP-kd cells occurred, while only 22 % of control
Huh7 cells failed to survive (Figure 4B) suggesting that
FBP1 suppressed the p53-mediated cellular response
to radiation-induced stress. High expression of FBP1
in Huh7 cells inhibits p53-mediated response to irradi-
ation treatment, while FBP-kd restores the sensitivity of
Huh7 cells to irradiation. Thus, FBP1 has a critical func-
tion in regulating p53 function, a key DNA intact keeper
and tumor suppressor. Recently, Liu et al. have shown that
binding of small molecule, PK7088, to Y220C mutant p53
in Huh7 cells restored its transcription activity similar
to that of wild-type p53 [45]. It would be interesting to
examine whether PK7088 disrupts the interaction of FBP1
with either mutant p53 or with BCCIP in Huh 7 cells
which may result in abrogating FBP1 mediated inhibition
of p53 function.
FBP1 was first found as a single-strand binding protein
that destabilizes the nucleic acid duplex [46,47]. FBP1
binds the pyrimidine-rich FUSE of human c-myc proto-
oncogene and activates c-myc transcription [18,48]. In a
mouse xenograft transplantation model, knockdown of
FBP1 in hepatocellular carcinoma cells resulted in high
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and tumor formation [19,49]. It has recently been shown
that JTV1/AIMP2/p38, a structural subunit of a multi-
amino acyl-tRNA synthetase (ARS) complex, interacts
with FBP1 and induces the expression of ubiquitin-specific
peptidase 29 (USP29) which, in turn, stabilizes p53 by pro-
moting deubiquitination [50]. It may be possible that
FBP1 may have an inhibitory effect on USP29 expression
that may be relieved by JTV1/AIMP2/p38 mediated se-
questering of FBP1. This contention is supported by the
fact that FBP1 is downregulated by JTV1/AIMP2/p38
[51]. In contrast, a splicing variant of AIMP2/p38 identi-
fied as DX2 competes with AIMP2/p38 for binding to p53
and promotes MDM2-mediated degradation of p53 [52].
It will be interesting to examine whether DX2 also com-
petes with AIMP2/p38 for binding to FBP1 and inhibits
FBP1 mediated induction of USP29, which in turn, may
have destabilizing effect on p53.
In this study, we demonstrated that FBP1 inhibits cell
sensitivity to irradiation, one means of treatment to obtain
cell death; It also impairs p21 expression by suppressing
p53 transactivation activity. The tumor harboring p53
mutation is often defective in transcription activity [53];
mice expressing defective p53 transcription activity are
predisposed to tumors [4]. In many of the tumors, the
tumor-suppressing activity of p53 may be subverted or
functionally compromised by other mechanisms. Many
cellular factors such as antagonism by TCTP [8], MDM2,
Sir2α [54] or by factors derived from pathogens such as
Tax from human T-cell leukemia virus type 1 [55], SV40
T large antigen [41], adenovirus E1B 55 K protein [56],
and hepatitis B virus X protein [57] are involved suppress-
ing the p53 activities.
By interacting with p53, TCTP blocks p53-induced tran-
scription activation of Bax and inhibits p53-dependent
apoptosis. Abrogation of the interaction between p53 and
TCTP-like protein can retrieve p53 tumor-inducing activ-
ity. Small molecules, such as nutlins and RITA can re-
trieve p53 tumor-suppressing activity by inhibiting the
interaction between MDM2 and p53 or binding with p53.
Our work clearly establishes FBP1 as a potential target,
just like MDM2, in the effort to develop drug that
are active against p53-bearing tumors. P53 transcrip-
tion activities refer to several factors, including Serine
phosphorylation [58], C-terminal acetylation [59,60] and
tetramer formation [61-63] and which of these mecha-
nisms is disrupted by interaction with FBP1 is yet to be
established.
Conclusion
It is our novel discovery that FBP1, which is abundantly
expressed in HCC tumors, is involved in the suppression
of transactivation activity of p53 by physically interacting
with p53 as well as its two regulatory proteins BCCIPand TCTP. The p53 transcription activity is enhanced in
FBP-kd cells resulting in increased sensitivity to radiation.
Since FBP1 expression in normal differentiated liver cells
is very low, our results suggest that over expression of
FBP1 may be involved in promoting HCC tumor by sup-
pressing p53 activity and could be a potential target for
drug development.
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